Summary of kidney cancer highlights from ASCO GU 2024

This summary shares important take-home messages from ASCO GU 2024 abstracts, including: Adjuvant pembrolizumab improves overall survival in all patients with high-risk kidney cancer compared with placebo, study findings don’t support the use of adjuvant nivolumab in patients with kidney cancer at high risk of returning after surgery, a study supports the use of injectable nivolumab for the treatment of advanced kidney cancer, and real-world data from a UK-based study of the avelumab plus axitinib combination.